Google
KAPA 株価分析 — Kairos Pharma, LTD. (Healthcare >> Biotechnology)
KAPA に関するよくある質問
KAPAのROE（自己資本利益率）は？
Kairos Pharma, LTD.のROEは-109.90%です。
KAPAの配当利回りは？
Kairos Pharma, LTD.の配当利回りは0.00%です。
KAPAの品質スコア（Quality Score）は？
当社のAIはKAPAの総合財務品質を100点中15点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
KAPAは今が買い時ですか？
当社AIのタイミングスコアは100点中28点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
KAPAはどのセクターに属しますか？
Kairos Pharma, LTD.はHealthcare >> Biotechnologyセクターに分類されます（NYSE MKT市場）
KAPA AI Analysis Summary
Our AI summary for KAPA: Kairos Pharma, LTD. (NYSE MKT), Healthcare >> Biotechnology sector. The stock currently trades at ROE of -109.90%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.31
Price
0.01
(2.07%)
Day Change
|
|
|---|
KAPA, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 43 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.31 |
| PBV / Sector |
1.21 / 5.20
GOOD
|
| Earning Per Share | -0.28 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
1.62 M
GREAT
|
| Average 1W Daily Value |
0.23 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:04 |
| Symbol | KAPA |
| Name | KAIROS PHARMA, LTD. |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE MKT |
| Listed Shares | 21.41 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 6.42 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2355 Westwood Blvd., Los Angeles, CA, United States, 90064
Phone: 310 948 2356
Website: https://kairospharma.com
Sector: Healthcare >> Biotechnology
Description: Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company's products under the preclinical stage include KROS 201 that activates T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist designed to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, as well as a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions for the treatment of autoimmune disease; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor that targets tumor cells in RelA/p65 biomarker-positive solid tumors for the treatment of triple-negative breast cancer; KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13, reversing tumor associated macrophage inhibition that blocks the IL4/IL13 cytokine immune receptors for the treatment of triple-negative breast cancer; and ENV 205, an antibody fragment that targets mitochondrial DNA for the treatment of prostate cancer. The company also develops ENV-105 (carotuximab). The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
